Get To Know Us

Thomas Hofmann, M.D., Ph.D.

Thomas Hofmann, M.D., Ph.D.

Chief Medical Officer (acting)

Dr. Thomas Hofmann has spent more than 25 years as a clinical developer of inhaled therapies for lung diseases and is an international leader in the study and treatment of pulmonary diseases such as Cystic Fibrosis, Asthma, COPD and Bronchiectasis. Most recently he served as Chief Scientific Officer of MannKind Corporation, following the acquisition of Qrumpharma, a pharmaceutical company he founded. Previously, Dr Hofmann held multiple executive positions in the pharmaceutical industry, including at Aumapharma LLC, Activaero GmbH, Discovery Labs, Corus Pharma, and Pulmopharm. Earlier he served as an adjunct professor of biomedical engineering at Temple University. He is the holder of numerous patents related to pulmonary diseases therapies and widely published in medical journals on the subject of treatment of lung diseases, and is a recipient of the Milton Graub Clinical Achievement Award from the U.S. Cystic Fibrosis Foundation. He earned his MD and PhD at Justus Liebig University Giessen in Germany and completed postdoctoral research in cystic fibrosis at University of North Carolina School of Medicine.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.